International expert consensus on the management of allergic rhinitis (AR) aggravated by air pollutants: Impact of air pollution on patients with AR: Current knowledge and future strategies
Overview
Paper Summary
Air pollution worsens allergic rhinitis symptoms through complex interactions involving oxidative stress and inflammatory pathways. Managing AR aggravated by air pollution requires a multi-pronged approach, including standard AR treatment, reducing exposure to pollutants, and potentially using antioxidants, though more research is needed on specific therapies for this combined condition.
Explain Like I'm Five
Scientists found that when the air is dirty with smoke and dust, it makes your nose allergies even worse. To feel better, you can take your medicine and try to avoid the dirty air.
Possible Conflicts of Interest
Some authors have disclosed relationships with pharmaceutical companies involved in allergy treatment, including Lyra, Sanofi, Actos, Optinose, Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Takeda, Teva, Uriach, Kyomed, BI, ALK, Stallergens, GSK, Hal, AZ, MSD, Danone, Novartis, Chiesi, AstraZeneca, Aché, FDA Allergenic, Boehringer Ingelheim, MEDA, Allergy Therapeutics, Chattem, US EPA, and CDC.
Identified Limitations
Rating Explanation
This review provides a comprehensive overview of the impact of air pollution on allergic rhinitis, summarizing current knowledge and identifying key mechanisms like oxidative stress. While limited by the nature of a review and potential conflicts of interest, it highlights important areas for future research and offers practical recommendations for patients and clinicians.
Good to know
This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →